A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-α antibody afelimomab in patients with sepsis syndrome
Crossref DOI link: https://doi.org/10.1007/s001340100973
Published Online: 2014-04-20
Published Print: 2001-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Gallagher, James
Fisher, Charles
Sherman, Bruce
Munger, Mark
Meyers, Bruce
Ellison, Travis
Fischkoff, Steven
Barchuk, William T.
Teoh, Leah
Velagapudi, Raja
Text and Data Mining valid from 2001-07-01